Cover ImageSALE
市場調查報告書

美國的固態腫瘤檢驗市場:2016∼2020年

Solid Tumor Testing Market in the US 2018-2022

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 353218
出版日期 內容資訊 英文 109 Pages
訂單完成後即時交付
價格
Back to Top
美國的固態腫瘤檢驗市場:2016∼2020年 Solid Tumor Testing Market in the US 2018-2022
出版日期: 2018年05月03日 內容資訊: 英文 109 Pages
簡介

固態腫瘤檢驗或篩檢為了早期發現癌症而進行,可進行防止癌症細胞擴散全身的有效治療。除了檢查尿和血液等檢體,為了分析特定的遺傳基因變異也有伴隨遺傳基因檢驗的情況。美國的固態腫瘤檢驗市場,預計2016∼2020年以年複合成長率11.1%擴大。

本報告提供美國的固態腫瘤檢驗市場現狀與今後的成長預測、市場趨勢、市場成長的課題、主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

  • 市場焦點

第5章 美國的醫療改革

  • 美國的醫療改革帶給癌症檢驗產業影響

第6章 償付及補償:概要

  • 目前方案:診斷檢驗的評估
  • 美國的報銷問題結構
  • 償付政策的課題

第7章 市場情況

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第8章 各技術市場區隔

  • 傳統的檢驗
  • 遺傳基因檢驗

第9章 癌症的各類型市場區隔

  • 乳癌
  • 肺癌
  • 大腸癌
  • 前列腺癌
  • 子宮頸癌
  • 其他

第10章 推動市場的要素

  • 對個人化醫療的高需求
  • 醫療制度的修改
  • 對POC檢驗的需求的增加
  • 分子檢驗的增加

第11章 促進要素的影響

第12章 市場課題

  • 正確的癌症檢測套組的不足
  • 法律規章的課題
  • 熟練技術人員的不足

第13章 促進要素及課題的影響

第14章 市場趨勢

  • 桌面式質譜儀的使用
  • 馬上能使用的試劑

第15章 供應商環境

  • 競爭模式
  • 市場佔有率:2015年
  • 其他值得注意的供應商

第16章 附錄

第17章 關於Technavio

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: IRTNTR21773

About Solid Tumor Testing

Solid tumor testing is a medical procedure that helps in the early detection of cancer. It is done to avoid the spread of cancerous cells throughout the body and allow for effective treatment.

Technavio's analysts forecast the solid tumor testing market in the US to grow at a CAGR of 10.72% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the solid tumor testing market in the US for 2018-2022. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

Technavio's report, Solid Tumor Testing Market in the US 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Agilent Technologies
  • Becton, Dickinson and Company
  • Danaher
  • F. Hoffmann-La Roche
  • Illumina
  • Thermo Fisher Scientific

Market driver

  • Growing prevalence of cancer
  • For a full, detailed list, view our report

Market challenge

  • High cost of sequencing
  • For a full, detailed list, view our report

Market trend

  • Adoption of NGS in cancer diagnostics
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 06: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 07: MARKET SEGMENTATION BY TECHNOLOGY

  • Segmentation by technology
  • Comparison by technology
  • Conventional testing - Market size and forecast 2017-2022
  • Non-conventional testing - Market size and forecast 2017-2022
  • Market opportunity by technology

PART 08: CUSTOMER LANDSCAPE

PART 09: SEGMENTATION BY END-USER

  • Segmentation by end-user
  • Comparison by end-user
  • Hospitals - Market size and forecast 2017-2022
  • Diagnostic laboratories - Market size and forecast 2017-2022
  • Academic and research institutes - Market size and forecast 2017-2022
  • Market opportunity by end-user

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

  • Adoption of NGS in cancer diagnostics
  • Preference for liquid biopsy over traditional biopsy
  • Increase in investment in cancer research

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Agilent Technologies
  • Becton, Dickinson and Company
  • Danaher
  • F. Hoffmann-La Roche
  • Illumina
  • Thermo Fisher Scientific

PART 15: APPENDIX

  • List of abbreviations

List of Exhibits

  • Exhibit 01: Related market
  • Exhibit 02: Market characteristics
  • Exhibit 03: Market segments
  • Exhibit 04: Market definition - Inclusions and exclusions checklist
  • Exhibit 05: Market size 2017
  • Exhibit 06: Validation techniques employed for market sizing 2017
  • Exhibit 07: Solid tumor testing market in the US- Market size and forecast 2017-2022 ($ bn)
  • Exhibit 08: Solid tumor testing market in the US - Year-over-year growth 2018-2022 (%)
  • Exhibit 09: Five forces analysis 2017
  • Exhibit 10: Five forces analysis 2022
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2017 and 2022
  • Exhibit 17: Solid tumor testing market in the US by technology - Market share 2017-2022 (%)
  • Exhibit 18: Comparison by technology
  • Exhibit 19: Conventional tests for solid tumors associated with various types of cancer
  • Exhibit 20: Conventional testing - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 21: Conventional testing - Year over year growth 2018-2022 (%)
  • Exhibit 22: Non-conventional testing - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 23: Non-conventional testing - Year over year growth 2018-2022 (%)
  • Exhibit 24: Market opportunity by technology
  • Exhibit 25: Customer landscape
  • Exhibit 26: Solid tumor testing market in the US by end-user - Market share 2017-2022 (%)
  • Exhibit 27: Comparison by end-user
  • Exhibit 28: Hospitals - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 29: Hospitals - Year over year growth 2018-2022 (%)
  • Exhibit 30: Diagnostic laboratories - Market size and forecast 2017-2022 ($ bn)
  • Exhibit 31: Diagnostic laboratories - Year over year growth 2018-2022 (%)
  • Exhibit 32: R&D funding for cancer 2013-2016 ($ millions)
  • Exhibit 33: Academic and research institutes- Market size and forecast 2017-2022 ($ bn)
  • Exhibit 34: Academic and research institutes - Year over year growth 2018-2022 (%)
  • Exhibit 35: Market opportunity by end-user
  • Exhibit 36: Cost of sequencing per genome 2001-2015 ($)
  • Exhibit 37: Vendor landscape
  • Exhibit 38: Landscape disruption
  • Exhibit 39: Vendors covered
  • Exhibit 40: Vendor classification
  • Exhibit 41: Market positioning of vendors
  • Exhibit 42: Agilent Technologies overview
  • Exhibit 43: Agilent Technologies- Business segments
  • Exhibit 44: Agilent Technologies - Organizational developments
  • Exhibit 45: Agilent Technologies - Geographic focus
  • Exhibit 46: Agilent Technologies - Segment focus
  • Exhibit 47: Agilent Technologies - Key offerings
  • Exhibit 48: Becton, Dickinson and Company overview
  • Exhibit 49: Becton, Dickinson and Company - Business segments
  • Exhibit 50: Becton, Dickinson and Company - Organizational developments
  • Exhibit 51: Becton, Dickinson and Company - Geographic focus
  • Exhibit 52: Becton, Dickinson and Company - Segment focus
  • Exhibit 53: Becton, Dickinson and Company - Key offerings
  • Exhibit 54: Danaher overview
  • Exhibit 55: Danaher - Business segments
  • Exhibit 56: Danaher - Organizational developments
  • Exhibit 57: Danaher- Geographic focus
  • Exhibit 58: Danaher- Segment focus
  • Exhibit 59: Danaher - Key offerings
  • Exhibit 60: F. Hoffmann-La Roche overview
  • Exhibit 61: F. Hoffmann-La Roche- Business segments
  • Exhibit 62: F. Hoffmann-La Roche - Organizational developments
  • Exhibit 63: F. Hoffmann-La Roche- Geographic focus
  • Exhibit 64: F. Hoffmann-La Roche- Segment focus
  • Exhibit 65: F. Hoffmann-La Roche - Key offerings
  • Exhibit 66: Illumina overview
  • Exhibit 67: Illumina - Business segments
  • Exhibit 68: Illumina - Organizational developments
  • Exhibit 69: Illumina - Geographic focus
  • Exhibit 70: Illumina - Segment focus
  • Exhibit 71: Illumina - Key offerings
  • Exhibit 72: Thermo Fisher Scientific overview
  • Exhibit 73: Thermo Fisher Scientific- Business segments
  • Exhibit 74: Thermo Fisher Scientific- Organizational developments
  • Exhibit 75: Thermo Fisher Scientific- Geographic focus
  • Exhibit 76: Thermo Fisher Scientific- Segment focus
  • Exhibit 77: Thermo Fisher Scientific- Key offerings
Back to Top